This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Horizon Pharma plc
Drug Names(s): interferon gamma-1b, Imukin, IMUKINE, Immukin, Immukine
Description: Actimmune is a recombinant interferon gamma 1b, a naturally occurring human protein that stimulates the immune system. Interferon gamma has a wide spectrum of biologic effects including: anti-infective, anti-viral, anti-fibrotic, anti-proliferative, immunomodulatory and chemosensitization.
InterMune no longer reports revenues for Actimmune as of Q2 2012.
Revenue splits for this drug are BioMedTracker estimates.
InterMune and Genentech
In 1998, InterMune obtained a license under Genentech's patents relating to interferon gamma-1b. The license from Genentech terminates on the later of May 5, 2018 and the date that the last of the patents licensed under the agreement expires. InterMune's rights include exclusive and non-exclusive rights under Genentech's patents. The exclusive licenses include the right to develop and commercialize Actimmune in the United States and Canada for the treatment and prevention of all human diseases and conditions, including infectious diseases, pulmonary fibrosis and cancer, but excluding arthritis and cardiac and cardiovascular diseases and conditions. The non-exclusive rights include a license to make or have made Actimmune for clinical and commercial purposes within InterMune's field of use in the United States...See full deal structure in Biomedtracker
Partners: Boehringer Ingelheim GmbH GlaxoSmithKline plc Roche Holding AG
Pink Sheet Actimmune oncology program ends
Additional information available to subscribers only: